Table 1.
Baseline characteristics of the patients.
| Variable | Number of patients/Value | Percentage (%) | |
|---|---|---|---|
| Gender | Male | 80 | 77.67 |
| Female | 23 | 22.33 | |
| Age | Median | 61 | — |
| Scope | 24–77 | ||
| ECOG PS | 0 | 17 | 16.50 |
| 1 | 86 | 83.50 | |
| Body mass index | Mean value | 23.4 | — |
| Scope | 15.8–31.2 | ||
| Tumor type | Lung cancer | 51 | 49.51 |
| Melanoma | 15 | 14.56 | |
| Esophageal cancer | 11 | 10.68 | |
| Liver cancer | 9 | 8.74 | |
| Urothelial carcinoma | 7 | 6.80 | |
| Gastric cancer | 5 | 4.85 | |
| Other types of tumors | 5 | 4.85 | |
| Distant metastasis | No distant organ metastasis | 65 | 63.10 |
| One or more distant metastatic cancers | 38 | 36.90 | |
| Prior therapy | Chemotherapy | 67 | 65.05 |
| Radiotherapy | 22 | 21.36 | |
| Targeted therapy | 8 | 7.77 | |
| Immunotherapy | 3 | 2.91 | |
| Other therapies (interferon therapy and interventional/radiofrequency ablation therapy) | 9 | 8.74 | |
| Treatment lines | First-line | 26 | 25.24 |
| Nonfirst-line | 77 | 74.76 | |
| Treatment regimen | Anti-PD-1 | 80 | 77.67 |
| Anti-PD-L1 | 13 | 12.62 | |
| Anti-PD-1 + anti-CTLA-4 | 10 | 9.71 |
—Represents no usability data.